CN111407881A - 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物 - Google Patents

神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物 Download PDF

Info

Publication number
CN111407881A
CN111407881A CN201911412811.1A CN201911412811A CN111407881A CN 111407881 A CN111407881 A CN 111407881A CN 201911412811 A CN201911412811 A CN 201911412811A CN 111407881 A CN111407881 A CN 111407881A
Authority
CN
China
Prior art keywords
nrg
neuregulin
myocardial infarction
administration
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201911412811.1A
Other languages
English (en)
Chinese (zh)
Inventor
周明东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zensun Shanghai Science and Technology Ltd
Original Assignee
Zensun Shanghai Science and Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zensun Shanghai Science and Technology Ltd filed Critical Zensun Shanghai Science and Technology Ltd
Priority to AU2020206381A priority Critical patent/AU2020206381B2/en
Priority to US17/420,974 priority patent/US20220096599A1/en
Priority to CA3125377A priority patent/CA3125377A1/en
Priority to EP20738153.4A priority patent/EP3909599A4/en
Priority to PCT/CN2020/070299 priority patent/WO2020143548A1/zh
Priority to JP2021539453A priority patent/JP7630173B2/ja
Publication of CN111407881A publication Critical patent/CN111407881A/zh
Priority to JP2024219524A priority patent/JP7825894B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201911412811.1A 2019-01-07 2019-12-31 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物 Pending CN111407881A (zh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2020206381A AU2020206381B2 (en) 2019-01-07 2020-01-03 Method for preventing, treating or delaying myocardial damage using neuregulin and composition
US17/420,974 US20220096599A1 (en) 2019-01-07 2020-01-03 Method for preventing, treating or delaying myocardial damage using neuregulin and composition
CA3125377A CA3125377A1 (en) 2019-01-07 2020-01-03 Method for preventing, treating or relieving myocardial injury using neuregulin and composition therefor
EP20738153.4A EP3909599A4 (en) 2019-01-07 2020-01-03 METHOD OF PREVENTING, TREATMENT OR DELAYING MYOCARDIAL DAMAGE USING NEUREGULIN AND COMPOSITION
PCT/CN2020/070299 WO2020143548A1 (zh) 2019-01-07 2020-01-03 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物
JP2021539453A JP7630173B2 (ja) 2019-01-07 2020-01-03 ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物
JP2024219524A JP7825894B2 (ja) 2019-01-07 2024-12-16 ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910015257 2019-01-07
CN2019100152577 2019-01-07

Publications (1)

Publication Number Publication Date
CN111407881A true CN111407881A (zh) 2020-07-14

Family

ID=71485079

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911412811.1A Pending CN111407881A (zh) 2019-01-07 2019-12-31 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物

Country Status (7)

Country Link
US (1) US20220096599A1 (https=)
EP (1) EP3909599A4 (https=)
JP (2) JP7630173B2 (https=)
CN (1) CN111407881A (https=)
AU (1) AU2020206381B2 (https=)
CA (1) CA3125377A1 (https=)
WO (1) WO2020143548A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118236430B (zh) * 2024-04-07 2025-08-26 中国人民解放军总医院第六医学中心 一种修复肿瘤治疗心肌损伤的药物组合物及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1498656A (zh) * 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
CN101394861A (zh) * 2005-12-30 2009-03-25 上海泽生科技开发有限公司 纽兰格林持续给药能改善心脏功能
WO2011091723A1 (en) * 2010-01-29 2011-08-04 Zensun (Shanghai) Science & Technology Limited Neuregulin based compositions and uses thereof for preventing, treating or delaying the myocardial ischemia-reperfusion injury
CA2963322A1 (en) * 2014-10-17 2016-04-21 Zensun (Shanghai) Science & Technology Limited Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure
CN108474787A (zh) * 2015-09-25 2018-08-31 道格拉斯.B.索耶 用于治疗心脏损伤的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US20010041869A1 (en) 2000-03-23 2001-11-15 Causey James D. Control tabs for infusion devices and methods of using the same
US6589229B1 (en) 2000-07-31 2003-07-08 Becton, Dickinson And Company Wearable, self-contained drug infusion device
WO2003099320A1 (en) * 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US7144384B2 (en) 2002-09-30 2006-12-05 Insulet Corporation Dispenser components and methods for patient infusion device
US7128727B2 (en) 2002-09-30 2006-10-31 Flaherty J Christopher Components and methods for patient infusion device
US20050065760A1 (en) 2003-09-23 2005-03-24 Robert Murtfeldt Method for advising patients concerning doses of insulin
US7686787B2 (en) 2005-05-06 2010-03-30 Medtronic Minimed, Inc. Infusion device and method with disposable portion
JP5738516B2 (ja) * 2005-12-30 2015-06-24 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
CN103768582A (zh) * 2006-12-29 2014-05-07 上海泽生科技开发有限公司 纽兰格林持续给药能改善心脏功能
CN102245189B (zh) * 2008-12-03 2015-06-17 阿莫塞特公司 改善梗死区灌注的组合物以及血管损伤修复方法
CN102470161A (zh) * 2009-06-09 2012-05-23 上海泽生科技开发有限公司 神经调节蛋白用于治疗心力衰竭的有效剂量
JP6096262B2 (ja) * 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
WO2013053076A1 (en) * 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
CN103127579B (zh) 2011-11-21 2017-06-16 上海泽生科技开发股份有限公司 便携式注射泵的驱动系统
US10894815B2 (en) * 2012-10-08 2021-01-19 Zensun (Shanghai) Science & Technology, Co., Ltd. Compositions and methods for treating heart failure in diabetic patients
EP2964249A1 (en) * 2013-03-06 2016-01-13 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
RU2015154737A (ru) * 2013-05-22 2017-06-27 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. Пролонгированное высвобождение нейрегулина для лечения сердечной недостаточности
WO2018052374A1 (en) * 2016-09-14 2018-03-22 Agency For Science, Technology And Research Modulation of tjp1 expression to regulate regeneration of heart cells
JP2017125032A (ja) * 2017-02-20 2017-07-20 ゼンスン（シャンハイ）サイエンス アンド テクノロジー カンパニー リミテッド 糖尿病患者における心不全の治療用組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1498656A (zh) * 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
CN101394861A (zh) * 2005-12-30 2009-03-25 上海泽生科技开发有限公司 纽兰格林持续给药能改善心脏功能
WO2011091723A1 (en) * 2010-01-29 2011-08-04 Zensun (Shanghai) Science & Technology Limited Neuregulin based compositions and uses thereof for preventing, treating or delaying the myocardial ischemia-reperfusion injury
CA2963322A1 (en) * 2014-10-17 2016-04-21 Zensun (Shanghai) Science & Technology Limited Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure
CN108474787A (zh) * 2015-09-25 2018-08-31 道格拉斯.B.索耶 用于治疗心脏损伤的方法

Also Published As

Publication number Publication date
EP3909599A4 (en) 2022-09-28
EP3909599A1 (en) 2021-11-17
JP7630173B2 (ja) 2025-02-17
JP7825894B2 (ja) 2026-03-09
WO2020143548A1 (zh) 2020-07-16
CA3125377A1 (en) 2020-07-16
AU2020206381B2 (en) 2026-01-22
JP2025060703A (ja) 2025-04-10
AU2020206381A1 (en) 2021-07-29
US20220096599A1 (en) 2022-03-31
JP2022516199A (ja) 2022-02-24

Similar Documents

Publication Publication Date Title
US20250360078A1 (en) Extended release of neuregulin for treating heart failure
JP2022153417A (ja) 駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物
CN109276705B (zh) 治疗糖尿病患者心力衰竭的组份和方法
CN109010801A (zh) 治疗心力衰竭的组份和方法
JP7825894B2 (ja) ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物
WO2020035012A1 (zh) 神经调节蛋白多肽片段及其用途
JP2017125032A (ja) 糖尿病患者における心不全の治療用組成物
JP2019112442A (ja) 糖尿病患者における心不全の治療用組成物および治療法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination